PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: collection of blood and tumor samples.
- Who it may be relevant to
- Registry conditions: Pancreatic Cancer Non-resectable. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT: PANDORE-PANC-IPC 2021-082
Overview
The study consists of a 25 ml blood sample collection: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression Collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.
Interventions
- Other collection of blood and tumor samples
The study consists of the collection of a 25 ml blood sample: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression At the time of collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * During a tumor biopsy in case of recurrence or progression (optional) and a questi
Primary outcome measures
- Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma [Time frame: up to 6 years]
Eligibility criteria
Inclusion criteria
- Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)
- No previous treatment with surgery or chemotherapy
- Age > 18 years
- General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)
- Therapeutic management at the Paoli-Calmettes Institute
- Signature of the informed consent specific to the PANDORE-PANC study
- Patient affiliated to a social security system or benefiting from such a system
Exclusion criteria
- Metastatic disease
- Pancreatic tumor of a histological type other than adenocarcinoma
- Other tumor under treatment or for which treatments have been completed for < 1 year
- Pregnant or breastfeeding women
- Person in an emergency situation
- Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT05802485 · PANDORE-PANC-IPC 2021-082